Pharma Journalist -

Castle Biosciences, Inc. announced that it has completed its acquisition of AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the…
Read More...

Virpax Pharmaceuticals, Inc. a company specializing in developing non-addictive product candidates for pain management, CNS disorders and anti-viral indications, reported preclinical…
Read More...

Pfizer Inc. and BioNTech SE submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a 10-µg booster dose of the Pfizer-BioNTech…
Read More...

Isleworth Healthcare Acquisition Corp. a special purpose acquisition company and Cytovia Holdings, Inc.("Cytovia"), a biopharmaceutical company empowering natural killer (NK) cells to…
Read More...

STRIDE regimen of a single priming dose of tremelimumab added to Imfinzi is the first dual immune checkpoint blockade regimen to improve overall survival in a Phase III trial in…
Read More...

Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation tumor-infiltrating lymphocyte (“TIL”) therapy and viral immunotherapy designed to treat and…
Read More...

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Veklury (remdesivir) for the treatment of…
Read More...

Valneva SE a specialty vaccine company, today provided an update on the rolling review process of its inactivated, COVID-19 vaccine candidate, VLA2001, with the Committee for Medicinal…
Read More...

The University of Tokyo and Astellas Pharma Inc. entered the second phase of their collaboration for co-creating innovative new medicines and medical solutions, called the Astellas…
Read More...

Roche announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq (atezolizumab) as an adjuvant…
Read More...